Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Acrux Ltd Announces First European Approval For Axiron


Sunday, 6 Oct 2013 05:43pm EDT 

Acrux Ltd announced that Axiron is now approved in Germany, for testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests. The approval of Axiron in Germany was granted after the European decentralised procedure was closed with a positive recommendation on the drug. 

Company Quote

1.285
0.11 +9.36%
19 Dec 2014